Daily Stock Analysis, GEMP, Gemphire Therapeutics Inc, priceseries

Gemphire Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.31
Close
0.30
High
0.34
Low
0.29
Previous Close
9.08
Daily Price Gain
-8.78
YTD High
30.00
YTD High Date
Feb 12, 2020
YTD Low
0.29
YTD Low Date
Dec 30, 2019
YTD Price Change
-6.94
YTD Gain
-95.86%
52 Week High
30.00
52 Week High Date
Feb 12, 2020
52 Week Low
0.29
52 Week Low Date
Dec 30, 2019
52 Week Price Change
-19.86
52 Week Gain
-98.51%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
208.50
Jan 24. 2017
251.85
12 Trading Days
20.79%
Link
LONG
Mar 20. 2017
253.11
Mar 29. 2017
266.46
7 Trading Days
5.27%
Link
LONG
Jun 28. 2017
306.75
Aug 2. 2017
478.21
24 Trading Days
55.89%
Link
LONG
Aug 28. 2017
214.75
Sep 12. 2017
229.85
10 Trading Days
7.03%
Link
LONG
Jan 18. 2018
198.00
Feb 2. 2018
240.66
11 Trading Days
21.54%
Link
LONG
Mar 1. 2018
175.00
Mar 13. 2018
187.65
8 Trading Days
7.23%
Link
LONG
May 31. 2018
155.00
Jun 11. 2018
168.68
7 Trading Days
8.83%
Link
LONG
Sep 5. 2018
39.25
Sep 25. 2018
50.98
14 Trading Days
29.89%
Link
LONG
Jan 11. 2019
22.25
Jan 29. 2019
25.69
11 Trading Days
15.44%
Link
LONG
Feb 22. 2019
29.50
Mar 8. 2019
32.95
10 Trading Days
11.71%
Link
LONG
Apr 1. 2019
29.69
Apr 12. 2019
31.37
9 Trading Days
5.68%
Link
LONG
Jan 31. 2020
9.10
Feb 5. 2020
9.63
3 Trading Days
5.80%
Link
LONG
Mar 24. 2020
10.97
Mar 30. 2020
11.87
4 Trading Days
8.20%
Link
LONG
Apr 2. 2020
14.27
Apr 7. 2020
15.21
3 Trading Days
6.60%
Link
Company Information
Stock Symbol
GEMP
Exchange
NasdaqGM
Company URL
http://www.gemphire.com
Company Phone
248-980-6538
CEO
Charles L. Bisgaier
Headquarters
Michigan
Business Address
17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA, MI 48152
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001638287
About

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of dyslipidemia. Its product under the Gemcabene name is used an adjunctive therapy to reduce low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and triglycerides. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Northville, MI.

Description

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan.